| Peer-Reviewed

Cost-Effectiveness Analysis of Insulin Pump Therapy for Patients with Type 2 Diabetes Mellitus in the Perioperative Period

Received: 7 August 2022     Accepted: 21 August 2022     Published: 27 August 2022
Views:       Downloads:
Abstract

Objective: In recent years, insulin pump, as one of the effective glycemic control therapy in perioperative hyperglycemia patients, has been gradually applied and promoted in clinical type 2 diabetes patients, but there is a contradictory statements of whther it is ecomonical. To analyze the cost and effect of perioperative insulin pump treatment in patients with type 2 diabetes, this artical compared the cost-effectiveness of glucose control in the perioperative insulin pump treatment group (CSII group) with multiple daily subcutaneous insulin treatment group (MDI group) and subcutaneous insulin + oral hypoglycemic drug treatment group (subcutaneous + oral treatment group). Methods: This study is based on the cost-effectiveness analysis method, compared the difference in glucose-control treatment costs and treatment effect of the three perioperative glucose control schemes, and conducted the sensitivity analysis of the corresponding indicators. Results: The comparison of the basic data between the three patient groups was not significantly significant (P > 0.05), and it was comparable. The fastest in CSII was (3.52 ± 2.94) days, and the incidence of postoperative infection in CSII patients was basically the same as that in the subcutaneous + oral treatment group, with 12.9% and 12.5%, respectively. The savings in CSII, MDI and subcutaneous + oral treatment by 1d were 609.07, 343.83 and 311.25, respectively, much more in CSII than MDI and subcutaneous + oral treatment; reducing the postoperative infection rate by 1 percentage point was 166.20, 60.34 and 135.70, respectively, in CSII than MDI and subcutaneous + oral treatment. Comprehensive analysis shows that CSII has a good cost-effectiveness. The results of sensitivity analysis showed the credibility and stability of this study. Conclusions: Insulin pump treatment in perioperative type 2 diabetes patients is a cost-effectiveness treatment scheme, and it is very useful in perioperative type 2 diabetes patients.

Published in International Journal of Diabetes and Endocrinology (Volume 7, Issue 3)
DOI 10.11648/j.ijde.20220703.15
Page(s) 70-76
Creative Commons

This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.

Copyright

Copyright © The Author(s), 2022. Published by Science Publishing Group

Keywords

Perioperative, Type 2 Diabetes, Insulin Pump, Cost-Effectiveness Analysis

References
[1] Diabetes Branch of Chinese Medical Association. Chinese Guidelines for the Prevention and Treatment of Type 2 Diabetes (2020 edition). [J] Chinese Journal of Endocrinology and Metabolism, 2021, 37 (04): 311-398.
[2] Idf diabetes atlas 9th edition. [EB/OL]. http://www.diabetesatlas.org/.2021-10-30/2019-12-10.
[3] LF. M. Perioperative management of diabetes: translating evidence into practice. [J] Cleve Clin J Med, 2009, 76 (4): S53-S59.
[4] Xiaoyu Chen, Jiewei Huang, Yanping Li, et al. Status and analysis of patients with perioperative insulin pump.[J] Chinese Electronic Journal of Obesity and Metabolic Diseases, 2020, 6 (1): 41-46.
[5] Peiying Huang. Progress in blood glucose management in non-diabetic patients after surgery. [J] Chinese Journal of Clinicians (electronic edition). 2013, 7 (03): 1186-1188.
[6] Shanks AM, Woodrum DT, Kumar SS, et al. Intraoperative hyperglycemia is independently associated with infectious complications after non-cardiac surgery. [J] BMC Anesthesiology, 2018, 18 (1): 90.
[7] Alexiewicz JM, Kumar D, Smogorzewski M, et al. Polymorphonuclear Leukocytes in Non-Insulin-dependent Diabetes Mellitus: Abnormalities in Metabolism and Function. [J] Annals of Internal Medicine, 1995, 123 (12): 919-924.
[8] Offodile AC, Chou H-Y, Lin JA-J, et al. Hyperglycemia and risk of adverse outcomes following microvascular reconstruction of oncologic head and neck defects. [J] Oral Oncology, 2018, 79: 15-19.
[9] Jie Zhang. Current status of application and management of perioperative insulin pump in diabetic patients [J] Journal of Qilu Nursing. 2012, 18 (3): 48-49.
[10] Min Zhang, Fang Jiang, Wenming Li. Effect of team-based intervention on blood glucose control effect and self-care ability in diabetic patients treated by insulin pump [J]. Journal of Qilu Nursing, 2021, 27 (21): 161-163.
[11] Dequan Gui, Wentao Zhu, Na Zhang. Application Status and Existing Problems of cost-effectiveness Analysis in Pharmaceutical Economics Research. [J] China Pharmacy, 2009, 20 (11): 805-807.
[12] Du Yaling. Analysis of hospitalization cost of intensive insulin therapy in patients with type 2 diabetes. [D] Shihezi University, 2014.
[13] JieweiHuang, Yanping Li, Xiaohua Lu, et al. Construction of insulin pump application management path in patients with perioperative hyperglycemia. [J] Journal of Refrefresher Education, 2020, 35 (1): 1006-1009.
[14] Maojuan He, Xiuxia Zhou. Perioperative nursing observation of neurosurgery patients with diabetes mellitus [J]. Diabetes New World, 2017, 20 (21): 124-125.
[15] Yingmei Su. Perioperative care of 102 patients with diabetes [J]. Journal of Qiqihar Medical College, 2013, 34 (15): 2319-2320.
[16] Mcmanus L M, Bloodworth R C, Prihoda T J, et al. Agonist-dependent failure of neutrophil function i diabetes correlates with extent of hyperglycemia [J]. Leukoc Biol. 2001, 70 (3): 395-404.
[17] Chengli Liu, Cheng Wang, et al. Effect of immune nutrients on the incidence of infection after malignant obstructive jaundice and biliary stenting. [J]. Progress in Modern Biomedical Sciences, 2017, 17 (05): 882-885.
[18] The Ministry of the People's Health of China. Diagnosis criteria for nosocomial infection (trial) [J]. Chinese Medical Journal, 2001, (05): 61-67.
[19] Roze S, Smith-Palmer J, Delbaere A, et al. cost-effectiveness of Continuous Subcutaneous Insulin Infusion Versus Multiple Daily Injections in Patients with Poorly Controlled Type 2 Diabetes in Finland. [J]. Diabetes Therapy, 2019, 10 (2): 563-574.
[20] Wei Yang, Linlang Liang, Ping Li, et al. Analysis of the cost and benefit of intensive insulin pump therapy in hospitalized diabetes [J]. Shenyang Army Medicine 2010, 23 (01): 49-51.
Cite This Article
  • APA Style

    Na Li, Jiewei Huang, Peiru Zhou, Xueyan Liu, Xiaohua Lu, et al. (2022). Cost-Effectiveness Analysis of Insulin Pump Therapy for Patients with Type 2 Diabetes Mellitus in the Perioperative Period. International Journal of Diabetes and Endocrinology, 7(3), 70-76. https://doi.org/10.11648/j.ijde.20220703.15

    Copy | Download

    ACS Style

    Na Li; Jiewei Huang; Peiru Zhou; Xueyan Liu; Xiaohua Lu, et al. Cost-Effectiveness Analysis of Insulin Pump Therapy for Patients with Type 2 Diabetes Mellitus in the Perioperative Period. Int. J. Diabetes Endocrinol. 2022, 7(3), 70-76. doi: 10.11648/j.ijde.20220703.15

    Copy | Download

    AMA Style

    Na Li, Jiewei Huang, Peiru Zhou, Xueyan Liu, Xiaohua Lu, et al. Cost-Effectiveness Analysis of Insulin Pump Therapy for Patients with Type 2 Diabetes Mellitus in the Perioperative Period. Int J Diabetes Endocrinol. 2022;7(3):70-76. doi: 10.11648/j.ijde.20220703.15

    Copy | Download

  • @article{10.11648/j.ijde.20220703.15,
      author = {Na Li and Jiewei Huang and Peiru Zhou and Xueyan Liu and Xiaohua Lu and Qingling Chen and Yan Zhou},
      title = {Cost-Effectiveness Analysis of Insulin Pump Therapy for Patients with Type 2 Diabetes Mellitus in the Perioperative Period},
      journal = {International Journal of Diabetes and Endocrinology},
      volume = {7},
      number = {3},
      pages = {70-76},
      doi = {10.11648/j.ijde.20220703.15},
      url = {https://doi.org/10.11648/j.ijde.20220703.15},
      eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ijde.20220703.15},
      abstract = {Objective: In recent years, insulin pump, as one of the effective glycemic control therapy in perioperative hyperglycemia patients, has been gradually applied and promoted in clinical type 2 diabetes patients, but there is a contradictory statements of whther it is ecomonical. To analyze the cost and effect of perioperative insulin pump treatment in patients with type 2 diabetes, this artical compared the cost-effectiveness of glucose control in the perioperative insulin pump treatment group (CSII group) with multiple daily subcutaneous insulin treatment group (MDI group) and subcutaneous insulin + oral hypoglycemic drug treatment group (subcutaneous + oral treatment group). Methods: This study is based on the cost-effectiveness analysis method, compared the difference in glucose-control treatment costs and treatment effect of the three perioperative glucose control schemes, and conducted the sensitivity analysis of the corresponding indicators. Results: The comparison of the basic data between the three patient groups was not significantly significant (P > 0.05), and it was comparable. The fastest in CSII was (3.52 ± 2.94) days, and the incidence of postoperative infection in CSII patients was basically the same as that in the subcutaneous + oral treatment group, with 12.9% and 12.5%, respectively. The savings in CSII, MDI and subcutaneous + oral treatment by 1d were 609.07, 343.83 and 311.25, respectively, much more in CSII than MDI and subcutaneous + oral treatment; reducing the postoperative infection rate by 1 percentage point was 166.20, 60.34 and 135.70, respectively, in CSII than MDI and subcutaneous + oral treatment. Comprehensive analysis shows that CSII has a good cost-effectiveness. The results of sensitivity analysis showed the credibility and stability of this study. Conclusions: Insulin pump treatment in perioperative type 2 diabetes patients is a cost-effectiveness treatment scheme, and it is very useful in perioperative type 2 diabetes patients.},
     year = {2022}
    }
    

    Copy | Download

  • TY  - JOUR
    T1  - Cost-Effectiveness Analysis of Insulin Pump Therapy for Patients with Type 2 Diabetes Mellitus in the Perioperative Period
    AU  - Na Li
    AU  - Jiewei Huang
    AU  - Peiru Zhou
    AU  - Xueyan Liu
    AU  - Xiaohua Lu
    AU  - Qingling Chen
    AU  - Yan Zhou
    Y1  - 2022/08/27
    PY  - 2022
    N1  - https://doi.org/10.11648/j.ijde.20220703.15
    DO  - 10.11648/j.ijde.20220703.15
    T2  - International Journal of Diabetes and Endocrinology
    JF  - International Journal of Diabetes and Endocrinology
    JO  - International Journal of Diabetes and Endocrinology
    SP  - 70
    EP  - 76
    PB  - Science Publishing Group
    SN  - 2640-1371
    UR  - https://doi.org/10.11648/j.ijde.20220703.15
    AB  - Objective: In recent years, insulin pump, as one of the effective glycemic control therapy in perioperative hyperglycemia patients, has been gradually applied and promoted in clinical type 2 diabetes patients, but there is a contradictory statements of whther it is ecomonical. To analyze the cost and effect of perioperative insulin pump treatment in patients with type 2 diabetes, this artical compared the cost-effectiveness of glucose control in the perioperative insulin pump treatment group (CSII group) with multiple daily subcutaneous insulin treatment group (MDI group) and subcutaneous insulin + oral hypoglycemic drug treatment group (subcutaneous + oral treatment group). Methods: This study is based on the cost-effectiveness analysis method, compared the difference in glucose-control treatment costs and treatment effect of the three perioperative glucose control schemes, and conducted the sensitivity analysis of the corresponding indicators. Results: The comparison of the basic data between the three patient groups was not significantly significant (P > 0.05), and it was comparable. The fastest in CSII was (3.52 ± 2.94) days, and the incidence of postoperative infection in CSII patients was basically the same as that in the subcutaneous + oral treatment group, with 12.9% and 12.5%, respectively. The savings in CSII, MDI and subcutaneous + oral treatment by 1d were 609.07, 343.83 and 311.25, respectively, much more in CSII than MDI and subcutaneous + oral treatment; reducing the postoperative infection rate by 1 percentage point was 166.20, 60.34 and 135.70, respectively, in CSII than MDI and subcutaneous + oral treatment. Comprehensive analysis shows that CSII has a good cost-effectiveness. The results of sensitivity analysis showed the credibility and stability of this study. Conclusions: Insulin pump treatment in perioperative type 2 diabetes patients is a cost-effectiveness treatment scheme, and it is very useful in perioperative type 2 diabetes patients.
    VL  - 7
    IS  - 3
    ER  - 

    Copy | Download

Author Information
  • Central Operating Room, the First Affiliated Hospital of Jinan University, Guangzhou, China

  • Central Operating Room, the First Affiliated Hospital of Jinan University, Guangzhou, China

  • Central Operating Room, the First Affiliated Hospital of Jinan University, Guangzhou, China

  • Department of Endocrinology and Metabolism, the First Affiliated Hospital of Jinan University, Guangzhou, China

  • Department of Endocrinology and Metabolism, the First Affiliated Hospital of Jinan University, Guangzhou, China

  • Department of Endocrinology and Metabolism, the First Affiliated Hospital of Jinan University, Guangzhou, China

  • Department of Endocrinology and Metabolism, the First Affiliated Hospital of Jinan University, Guangzhou, China

  • Sections